SP 20104

Drug Profile

SP 20104

Alternative Names: SP20104

Latest Information Update: 23 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sarfez Pharmaceuticals
  • Class Urologics
  • Mechanism of Action Renin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Focal segmental glomerulosclerosis

Most Recent Events

  • 23 Jan 2018 SP 20104 is still in phase II trials for Focal segmental glomerulosclerosis in USA (Sarfez Pharmaceuticals, January 2018)
  • 24 Nov 2017 Sarfez announces intention to submit NDA to US FDA for Focal segmental glomerulosclerosis in the third quarter of 2019 (Sarfez pipeline, November 2017)
  • 07 Dec 2015 Phase-II clinical trials in Focal segmental glomerulosclerosis in USA prior to December 2015 (Sarfez pipeline, December 2015 and November 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top